Pfizer hemophilia drug causes patient death, company responds

On December 23 local time, Pfizer stated that a patient participating in the company's long-term study on hemophilia drugs died after experiencing severe side effects. Pfizer's stock price closed down more than 1% that day. In response to the patient's death, Pfizer said in a statement, "Pfizer, along with the trial researchers and an independent external data monitoring committee, is actively collecting information to better understand the complex, multifactorial circumstances surrounding this event." The company also stated that based on its current understanding and overall clinical data collected so far, Pfizer expects that the patient's death will not have any impact on the safety of patients receiving the drug treatment.